Holen Sie sich die Stockscreener-App
0.00
100.00%
-123.96
Schlusskurs vom Vortag:
$123.96
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$9.81B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-450.07M
KGV:
0.00
EPS:
-6.0583
Netto-Cashflow:
$-312.79M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$123.99
Nuvalent Inc Stock (NUVL) Company Profile
Firmenname
Nuvalent Inc
Sektor
Branche
Telefon
508-446-2272
Adresse
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Compare NUVL vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
0.00 | 9.81B | 0 | -450.07M | -312.79M | -6.0583 |
VRTX
Vertex Pharmaceuticals Inc
|
519.51 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.74 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.54 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
146.69 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
205.11 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-06-24 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2026-05-22 | Eingeleitet | Bernstein | Outperform |
| 2026-03-30 | Eingeleitet | Wells Fargo | Overweight |
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-11-12 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-10-16 | Fortgesetzt | Stifel | Buy |
| 2025-10-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-09-04 | Fortgesetzt | Guggenheim | Buy |
| 2025-09-03 | Eingeleitet | Raymond James | Outperform |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-03-14 | Hochstufung | UBS | Neutral → Buy |
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-10-24 | Eingeleitet | UBS | Neutral |
| 2024-08-29 | Eingeleitet | Barclays | Overweight |
| 2024-04-17 | Eingeleitet | Jefferies | Buy |
| 2024-04-01 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-02-28 | Fortgesetzt | Guggenheim | Buy |
| 2024-02-23 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-09-27 | Eingeleitet | Stifel | Buy |
| 2023-08-08 | Eingeleitet | SVB Securities | Market Perform |
| 2023-07-24 | Eingeleitet | Guggenheim | Buy |
| 2023-01-18 | Eingeleitet | Wedbush | Outperform |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
Alle ansehen
Nuvalent Inc Aktie (NUVL) Neueste Nachrichten
NUVL Stock Surges 39% Premarket – Why Is GSK Buying This Boston-Based Oncology Company? - Stocktwits
GSK to Raise $6.5 Billion From US Debt Sale to Fund Nuvalent Acquisition - marketscreener.com
GSK to Raise $6.5 Billion From US Debt Sale to Fund Nuvalent Acquisition, Bloomberg Reports - marketscreener.com
GSK Commences Six-Part Dollar Bond Sale to Help Fund Nuvalent Acquisition - marketscreener.com
GSK Launches Six-Part Dollar Bond Sale to Support Nuvalent Acquisition Financing, Bloomberg Reports - marketscreener.com
Nuvalent, Inc. (NUVL) Stock Analysis: What Investors Need to Know About This $9.81 Billion Biotech Player - DirectorsTalk Interviews
Deerfield Management Announces Portfolio Company Nuvalent, Inc. to be Acquired by GSK - Eastern Progress
Nuvalent, Inc. (NUVL) Stock Analysis: Exploring the Biotech’s Steady Path with a $9.81 Billion Market Cap - DirectorsTalk Interviews
Nuvalent, Inc. (NUVL) Stock Analysis: Evaluating Growth Potential Amidst a Steady Market Position - DirectorsTalk Interviews
Nuvalent (NUVL) Results Review: EPS Does Not Reach the Reported Estimate in the Latest Reading; Latest Reaction: The Immediate Price Response Is Limited for the Current SessionEarnings Deceleration Risk - vinanet.vn
Nuvalent Number of Employees 2026 | Employee Count & Headcount Data - reveliolabs.com
Nuvalent, Inc. (NUVL) Stock Analysis: Steady at $123.96 with Phase 2 Clinical Trials on the Horizon - DirectorsTalk Interviews
Nuvalent, Inc. (NUVL) Stock Analysis: Navigating Biotech’s Uncharted Waters with Zero Upside - DirectorsTalk Interviews
Equity in earnings of Nuvalent, Inc. Class A – LS:A3CWDU - TradingView
Nuvalent Inc (NUVL) Stock Analysis & Forecast - TradingKey
Nuvalent Inc (NUVL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Enterprise value to EBIT forward of Nuvalent, Inc. Class A – LS:A3CWDU - TradingView
Nuvalent, Inc. (NUVL) Stock Analysis: A $9.79 Billion Biotech Game-Changer Facing Analyst Consensus - DirectorsTalk Interviews
Nuvalent Inc (NUVL) Institutional Confidence - TradingKey
Nuvalent, Inc. SEC Filing (Jul 27, 2026) - Stock Titan
Nuvalent Inc (NUVL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
NUVL|Nuvalent Inc|Price:123.965| - TradingKey
Nuvalent Inc (NUVL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Nuvalent Inc (NUVL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Nuvalent Inc (NUVL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Nuvalent Inc (NUVL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Nuvalent Inc (NUVL) Cash Flow - TradingKey
Nuvalent, Inc. Class A Revenue Breakdown – LS:A3CWDU - TradingView
GSK Lands Its First Lung Cancer Drug Days After Nuvalent Deal Closes - finance.biggo.com
FDA Approves NSCLC Treatment Acquired by GSK in Nuvalent Deal - Contract Pharma
GSK secures first lung cancer approval, validating $10.6bn Nuvalent bet - Yahoo Finance
GSK Lands FDA Approval for Nuvalent-Acquired Jideytro for NSCLC - Yahoo Finance
A Quick Look at Today's Ratings for Nuvalent(NUVL.US), With a Forecast Between $116 to $155 - Moomoo
GSK's $10.6B Nuvalent acquisition delivers first FDA approval ahead of schedule - The Business Journals
GSK secures first lung cancer approval as FDA clears Jideytro in quick payoff from Nuvalent deal - Fierce Pharma
Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer - PR Newswire
Bernstein initiates coverage of Nuvalent (NUVL) with outperform recommendation - MSN
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN), Nuvalent, Inc. (Nasd - Supply Chain Digital
How Nuvalent Inc. (NUVL) Affects Rotational Strategy Timing - Stock Traders Daily
Nuvalent, Inc. (NASDAQ:NUVL) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Wall Street Zen Upgrades Nuvalent (NASDAQ:NUVL) to Sell - MarketBeat
Deerfield group reports 0% ownership in Nuvalent (NUVL) Class A shares - Stock Titan
Deerfield holders cash out of Nuvalent (NUVL) at $124 per share - Stock Titan
Nuvalent, Inc.(NasdaqGM: ) dropped from Russell 2500 Growth Index - marketscreener.com
Halper Sadeh LLC is Investigating Whether ATAI, CCRN, NUVL are Obtaining Fair Deals for their Shareholders - GlobeNewswire
Nuvalent, Inc.(NasdaqGM: ) dropped from Russell 2000 Defensive Index - marketscreener.com
Form 4 Nuvalent Inc For: 15 July By Investing.com - Investing.com Canada
Nuvalent, Inc. (NUVL) director exits holdings in $124 GSK merger - Stock Titan
Nuvalent, Inc. (NUVL) CFO details tender offer and award cash-outs - Stock Titan
Form 4 Nuvalent Inc For: 15 July - Investing.com India
Nuvalent, Inc. (NUVL) director tenders stock in $124 GSK cash buyout - Stock Titan
Finanzdaten der Nuvalent Inc-Aktie (NUVL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.75%
3.18%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):